Trial Profile
An Open Label, Non-comparative Observational Study to Evaluate the Efficacy and Safety of Olmesartan Medoxomil Tablet 20mg in the Treatment of Mild to Moderate Essential Hypertension for 24 Weeks in Chinese Patients & a Sub-group of ABPM Study to Measure the T/P Ratio and Ambulatory Blood Pressure Change
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jun 2016
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms EXPO
- Sponsors Daiichi Sankyo Company
- 03 Jun 2016 New trial record